Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callYahoo Finance· February 28, 2026

NU Q4 Earnings Call Highlights

View original at finance.yahoo.com
NU Q4 Earnings Call Highlights NU logo Key Points 131 million customers after adding 17 million in 2025, with an 83% activity rate and ARPAC rising to $15 (+27% YoY), indicating stronger engagement and monetization potential…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The PROSOFIPO contribution was a non-recurring regulatory levy and not a reflection of the credit quality or the financial health of the Mexico operation

    80% confidence
  • Nu's ARPAC remains materially below incumbent competitors, providing runway for additional cross-sell and product expansion

    80% confidence
  • 2025 was a fantastic year for Nu

    80% confidence
  • Risk-adjusted net interest margin would have been broadly stable quarter-over-quarter excluding the PROSOFIPO contribution

    80% confidence
  • Available funding of $38.8 billion represented about twice the company's $19 billion net credit portfolio, providing headroom to scale credit while pursuing balance sheet optimization

    80% confidence
  • Finalizing the banking license process in Mexico is critical to unlocking the next phase of credit growth

    80% confidence
  • Without the FGTS headwind, sequential portfolio growth would have been about 13%-14% rather than roughly 11% (FX neutral)

    80% confidence
  • 2026 is described as an inflection year with three pillars: winning in core markets, strengthening foundations for international expansion, and AI as a superpower

    80% confidence
  • The drop in FGTS originations had been more than offset by growth in public payroll lending

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com